By crossing ApcMin/+ mice with GCB-LMP1/2A mice, we generated mice carrying both LMP1/2A antigens and ApcMin/+ mutation (referred to as ApcMin/+LMPKI) to assess whether LMP1/2A-induced immune surveillance could suppress intestinal tumor development. Here, PDLIM7 is linked to intestinal neoplasm.